ASTM has re-issued E3219 as E3219-25, the current reference for deriving health-based exposure limits. HBELs are a decade-old regulatory expectation, not a 2025 novelty — but the revision sharpens how limits are derived, documented and defended.
ASTM's guide on deriving health-based exposure limits has been re-issued as E3219-25. Health-based exposure limits are not a new idea — they have been the working regulatory expectation in shared-facility manufacture for the better part of a decade — but the 2025 edition is now the current reference for how a limit should be derived, documented and justified.
What happened
On its store page ASTM lists E3219-25, Standard Guide for Derivation of Health-Based Exposure Limits (HBELs), with status Active and a Last Updated stamp of 10 June 2025. The document is developed by Subcommittee E55.14 under Committee E55 (manufacture of pharmaceutical products), sits in Book of Standards Volume 14.01, runs to 33 pages and carries DOI 10.1520/E3219-25 (ICS 11.120.10).
The predecessor E3219-20 remains catalogued with the same title, committee and subcommittee, at 30 pages. Third-party catalogues record E3219-25 as superseding it, while some PDE/ADE calculation tooling still cites E3219-19 — a 2019 edition between the two. ASTM's own store shows no "supersedes" line, so the lineage reads E3219-19 → E3219-20 → E3219-25.
Why it matters
The scope has not narrowed. Clause 1.3 states the guide applies when calculating and documenting an HBEL for APIs (including biologics), intermediates, cleaning agents, excipients and other chemicals — explicitly reagents and manufacturing residues — used for cleaning validation and verification, cross-referencing Guides F3127 and E3106. Cleaning and cross-contamination of equipment and medical-device surfaces is in scope; leachables/extractables are not, deferred to the forthcoming ICH Q3E guideline.
Two further clauses matter at programme level. Clause 1.6 allows subsequent-product HBELs for specific routes of exposure (oral, inhalation, parenteral) where bioavailability differs, and for specific patient populations — the 50 kg standard adult is not a universal default, and paediatric formulations with lower target body weight are called out. Clause 1.4 confirms the same principles can underpin occupational exposure limits.
What is particularly interesting
Section 4.3 is where the revision is most visible from the public extract. Where E3219-20 allowed "alternative, purposefully conservative approaches (for example, TTC, read-across)", E3219-25 enumerates a richer set: TTC where applicable, read-across on structural or physico-chemical attributes, toxicokinetics and toxicodynamics (via a common mechanism of action or adverse outcome pathways), and new approach methodologies (NAMs) using in vitro assays and in silico modelling. It then attaches a caution: in vitro points of departure may underestimate the traditional in vivo PoD by a median of roughly 100-fold, and in vitro/in vivo correlation has been reported as poor. NAMs are permitted, but must be justified rather than quietly substituted for in vivo data.
Section 4.4 is re-anchored: where E3219-20 cited the EU GMP guidelines and an ISPE reference, E3219-25 states consistency with the EU GMP guidelines and the PIC/S HBEL guideline (PI 046) — a clearer tie to the inspection-facing document set. The five-step derivation logic in 4.5 is unchanged: hazard characterization; critical effect(s) with dose–response assessment; one or several points of departure; PoD-specific adjustment factors; and calculation plus justification of the selected HBEL.
What could we learn
The derivation method is settled; the practical difficulty is not the arithmetic but the documentation and justification of endpoint selection, adjustment factors and the final chosen HBEL. This revision widens the accepted evidence base while hardening the expectation that using it is argued explicitly — and the missing change log on the public page is a reminder that a paywall is no substitute for reading the standard before revising an SOP.
Questions worth asking in our own programme
- Do our HBEL/PDE documents state the route of exposure and target patient population explicitly, rather than inheriting a 50 kg adult default?
- If we use read-across, TTC or in vitro/in silico data, is the justification documented to the standard that section 4.3 now implies?
- Are HBELs in SOPs, protocols and validation reports cited against the current ASTM edition, including legacy assessments written against E3219-19 or E3219-20?
- Do our HBELs cover intermediates, cleaning agents, excipients and reagents, and not only the APIs?
- Where an HBEL also underpins an occupational exposure limit, is that dual use documented and reviewed by a qualified toxicologist?
- What trigger and interval do we apply for re-assessing existing HBELs when the toxicological database changes?
Wider context
HBELs entered European expectations through the EMA guideline for shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), adopted November 2014 and effective 1 June 2015, followed by the EMA Q&A of 19 April 2018 (EMA/CHMP/CVMP/SWP/246844/2018). PIC/S transposed these into PI 046, PI 052-1 and PI 053-1, in force 1 June 2020. The arithmetic still descends from ICH Q3C(R4) Appendix 3 and VICH GL 18: a point of departure divided by adjustment factors F1–F5 covering inter-species extrapolation, inter-individual variability, study duration, severity of toxicity and absence of a no-effect level. E3219-25 is thus a consolidation of an established concept; the operative question is not what changed in principle, but whether a site's documentation would survive inspection today.
Sources
- ASTM Store, E3219-25 — https://store.astm.org/e3219-25.html (Active; Last Updated 10 June 2025; E55/E55.14; Vol. 14.01; 33 pages; DOI 10.1520/E3219-25)
- ASTM Store, E3219-20 — https://store.astm.org/e3219-20.html (30 pages, same scope blocks)
- EMA guideline EMA/CHMP/CVMP/SWP/169430/2012, adopted 20 November 2014, effective 1 June 2015
- EMA Q&A EMA/CHMP/CVMP/SWP/246844/2018, 19 April 2018
- PIC/S PI 046 (HBEL guideline), PI 052-1 (aide-memoire) and PI 053-1 (Q&A), in force 1 June 2020
- Third-party catalogue records (supersedes E3219-20; publication recorded as 15 March 2025 on reseller pages)
Validation takeaway
ASTM E3219-25 does not change the principle of deriving a health-based exposure limit — it updates the evidence base the derivation may draw on and reinforces the requirement to justify endpoint selection, adjustment factors and the final selected HBEL. Teams should treat the new edition as a document-control and re-assessment trigger: confirm which edition each existing HBEL was written against, verify that non-API residues (intermediates, cleaning agents, excipients, reagents) are covered, and check that route of exposure and target patient population are stated rather than defaulted.
Questions worth asking in our own programme
- Do our HBEL/PDE documents state the route of exposure and target patient population explicitly, rather than inheriting a 50 kg adult default?
- If we rely on read-across, TTC or in vitro/in silico data, is the justification documented to the level ASTM E3219-25 section 4.3 now implies?
- Are HBELs in SOPs, protocols and validation reports cited against the current ASTM edition, including legacy assessments written against E3219-19 or E3219-20?
- Do our HBELs cover intermediates, cleaning agents, excipients and reagents, and not only the APIs?
- Where an HBEL also underpins an occupational exposure limit, is that dual use documented and reviewed by a qualified toxicologist?
- What trigger and interval do we apply for re-assessing existing HBELs when the toxicological database changes?
